Artegraft, Inc. Sustainability Profile
Artegraft, Inc., a leading name in the medical device industry, is headquartered in the United States and operates extensively across various regions. Founded in 2000, the company has established itself as a pioneer in the development of innovative grafting solutions, particularly for vascular and surgical applications. Artegraft's core offerings include biologically derived grafts that are designed to enhance patient outcomes through superior integration and performance. Their unique approach to tissue engineering sets them apart in a competitive market, allowing for improved healing and reduced complications. With a strong commitment to quality and innovation, Artegraft has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector. The company continues to advance its product line, contributing to the evolving landscape of surgical solutions.
DitchCarbon Score
How does Artegraft, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Artegraft, Inc.'s score of 5 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Artegraft, Inc.'s reported carbon emissions
Artegraft, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of LeMaitre Vascular, Inc., which may influence its climate commitments and emissions reporting. As of now, Artegraft has not established any documented reduction targets or initiatives, nor does it appear to have adopted any specific climate pledges. The lack of emissions data and reduction initiatives suggests that Artegraft may still be in the early stages of developing a comprehensive climate strategy. Given the context of its parent company, LeMaitre Vascular, Inc., Artegraft may benefit from any climate-related initiatives or targets set by its parent, although specific details on such cascaded commitments are not provided. Overall, Artegraft's current climate commitments and emissions profile remain undefined, highlighting an opportunity for the company to enhance its sustainability efforts in alignment with industry standards.
How Carbon Intensive is Artegraft, Inc.'s Industry?
How Carbon Intensive is Artegraft, Inc.'s Location?
Artegraft, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Artegraft, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
